Market Research Logo

Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2018

Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2018, provides an overview of the Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline landscape.

Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Symptoms include poor coordination, unsteady walk and a tendency to stumble, change in speech and difficulty swallowing.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.

Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (SCA) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Spinocerebellar Ataxia (SCA) - Overview
Spinocerebellar Ataxia (SCA) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spinocerebellar Ataxia (SCA) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spinocerebellar Ataxia (SCA) - Companies Involved in Therapeutics Development
Bio Blast Pharma Ltd
Biohaven Pharmaceutical Holding Company Ltd
Cadent Therapeutics
Ionis Pharmaceuticals Inc
Shionogi & Co Ltd
Spark Therapeutics Inc
Vybion Inc
WAVE Life Sciences Ltd
Spinocerebellar Ataxia (SCA) - Drug Profiles
2AU-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit ATXN3 for Spinocerebellar Ataxia Type 3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Ataxin-1 for Spinocerebellar Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Ataxin-7 for Spinocerebellar Ataxia Type 7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASO-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BHV-4157 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAD-1883 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Inhibit ATXN3 for Spinocerebellar Ataxia Type 3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
riluzole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RNAi Gene Therapy to Inhibit Ataxin-3 for Machado-Joseph Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rovatirelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trehalose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Spinocerebellar Ataxia (SCA) - Dormant Projects
Spinocerebellar Ataxia (SCA) - Product Development Milestones
Featured News & Press Releases
Oct 02, 2017: Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia Phase 2/3 Trial
Aug 07, 2017: Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017
Jun 05, 2017: Bioblast Pharma to Seek Strategic Alternatives Including Partnership and Merger Opportunities
May 30, 2017: Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole
May 15, 2017: Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA
Jan 26, 2017: Bioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2
Jan 18, 2017: Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)
Dec 22, 2016: Biohaven Enrolls First Patient in Pivotal Trial of BHV-4157 in Patients With Hereditary Spinocerebellar Ataxia
Jul 20, 2016: Biohaven Reports Dosing Of First Subject In Pharmacokinetic And Safety Trial Of BHV-4157
Jul 05, 2016: Biohaven Receives FDA Investigational New Drug Application (IND) Approval for BHV-4157
Jun 01, 2016: Scripps Florida Scientists Create Compound that Erases Disease-Causing RNA Defects
May 27, 2016: Announcement of Additional Clinical Trial of “KPS-0373 for the Treatment of Spinocerebellar Ataxia
May 25, 2016: Portage Announces Orphan Drug Designation Request Granted to Biohaven for BHV-4157
Mar 03, 2016: Portage Biohaven orphan drug designation request granted for the treatment of spinocerebellar ataxia
Sep 14, 2015: BioBlast Granted Patent From USPTO for Cabaletta for the Treatment of Spinocerebellar Ataxia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Spinocerebellar Ataxia (SCA), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Bio Blast Pharma Ltd, H1 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Cadent Therapeutics, H1 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Shionogi & Co Ltd, H1 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Spark Therapeutics Inc, H1 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Vybion Inc, H1 2018
Spinocerebellar Ataxia (SCA) - Pipeline by WAVE Life Sciences Ltd, H1 2018
Spinocerebellar Ataxia (SCA) - Dormant Projects, H1 2018
List of Figures
Number of Products under Development for Spinocerebellar Ataxia (SCA), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report